Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:9119 |
Name | acute myeloid leukemia |
Definition | A myeloid leukemia that is characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. |
Source | DiseaseOntology.org |
Alt Ids | DOID:9118 DOID:9171 |
Path | disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia myeloid leukemia acute myeloid leukemia |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00084695 | Phase II | Fludarabine Busulfan + Melphalan anti-thymocyte globulin Cyclophosphamide Prednisone | Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases | Unknown status | USA | 0 |
NCT00513474 | Phase I | Rasburicase Methotrexate Sirolimus Cyclosporine Tacrolimus Filgrastim Busulfan + Cyclophosphamide + Etoposide | Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant | Completed | USA | 0 |
NCT00679536 | Phase Ib/II | anti-thymocyte globulin + Busulfan + Fludarabine | Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors | Unknown status | USA | 0 |
NCT00801489 | Phase II | Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin | Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias | Recruiting | USA | 0 |
NCT00857389 | Phase II | Cyclophosphamide Filgrastim Tacrolimus Thiotepa anti-thymocyte globulin + Busulfan + Clofarabine Methotrexate | Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | Completed | USA | 0 |
NCT00866281 | Phase Ib/II | Midostaurin | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia | Terminated | USA | SWE | NLD | ITA | FRA | 0 |
NCT00887068 | Phase III | Azacitidine | Randomized Allogeneic Azacitidine Study | Completed | USA | 0 |
NCT00892190 | Phase I | Dasatinib | Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT00908167 | Phase I | Clofarabine + Cytarabine + Sorafenib | Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies | Completed | USA | 0 |
NCT00946647 | Phase II | Panobinostat Azacitidine | A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML). | Completed | USA | SWE | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | 2 |
NCT01028716 | Phase II | Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine | Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Terminated | USA | 0 |
NCT01084252 | Phase Ib/II | Isatuximab Dexamethasone + Isatuximab | Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies | Completed | USA | TUR | ITA | ISR | GRC | GBR | FRA | FIN | ESP | BRA | BEL | ARG | 5 |
NCT01093573 | Phase Ib/II | Azacitidine + Midostaurin | Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia | Completed | USA | 0 |
NCT01187810 | Phase I | Fenretinide Cytarabine Methotrexate | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | Terminated | USA | 0 |
NCT01211457 | Phase Ib/II | Sapacitabine + Venetoclax Decitabine + Sapacitabine | Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes | Unknown status | USA | 0 |
NCT01222143 | Phase Ib/II | Cytarabine + Etoposide + Mitoxantrone Nilotinib | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia | Terminated | CAN | 0 |
NCT01251575 | Phase II | Fludarabine Cyclosporine + Mycophenolate mofetil + Sirolimus | Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | DNK | 0 |
NCT01252667 | Phase II | Cyclosporine + Mycophenolate mofetil Clofarabine | Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant | Completed | USA | 0 |
NCT01266083 | Phase II | WT1 vaccine | Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) | Completed | USA | 0 |
NCT01303796 | Phase III | Decitabine + Sapacitabine Decitabine | A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS) | Completed | USA | SWE | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | BEL | AUT | 0 |
NCT01305499 | Phase II | Azacitidine + Entinostat | A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | 0 |
NCT01321346 | Phase I | Cytarabine Panobinostat | A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT01338987 | Phase II | Tacrolimus Busulfan Methotrexate Leuprolide Cyclophosphamide Fludarabine | Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation | Completed | USA | 0 |
NCT01352650 | Phase I | Decitabine + Plerixafor | Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT01371981 | Phase III | Cytarabine + Daunorubicin + Etoposide Sorafenib Cytarabine + Etoposide Cytarabine + Mitoxantrone Asparaginase + Cytarabine Bortezomib | Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | NZL | CAN | AUS | 1 |
NCT01398462 | Phase I | CWP232291 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Completed | USA | 1 |
NCT01449058 | Phase Ib/II | Alpelisib + Binimetinib | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | Completed | USA | ITA | GBR | FRA | ESP | CHE | AUS | 0 |
NCT01463046 | Phase I | Cytarabine + Daunorubicin + Panobinostat | Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT01483274 | Phase I | Decitabine | Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation | Withdrawn | USA | 0 |
NCT01498445 | Phase Ib/II | Dasatinib + Decitabine | An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) | Terminated | USA | 0 |
NCT01515527 | Phase II | Cytarabine Cladribine Decitabine | Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) | Recruiting | USA | 0 |
NCT01534260 | Phase Ib/II | Bortezomib + Sorafenib + Vorinostat | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype | Completed | USA | 0 |
NCT01546038 | Phase Ib/II | Glasdegib Cytarabine Decitabine Cytarabine + Daunorubicin | A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | POL | ITA | ESP | DEU | CAN | 0 |
NCT01578109 | Phase I | Sorafenib | Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01606579 | Phase Ib/II | Cytarabine + PRI-724 Dasatinib + PRI-724 PRI-724 | Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies | Completed | USA | 0 |
NCT01620216 | Phase II | Sunitinib Dasatinib Nilotinib Ponatinib Sorafenib | Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients | Terminated | USA | 0 |
NCT01621477 | Phase II | Plerixafor Tacrolimus Mycophenolate mofetil anti-thymocyte globulin + Busulfan + Clofarabine Cyclophosphamide + Cytarabine | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant | Terminated | USA | 0 |
NCT01621542 | Phase I | WT2725 | Clinical Study of WT2725 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT01627041 | Phase II | Cytarabine + Daunorubicin + Decitabine Cytarabine + Daunorubicin | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | Unknown status | USA | 0 |
NCT01634217 | Phase I | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | Completed | USA | 0 | |
NCT01640301 | Phase Ib/II | Aldesleukin WT1 sensitized T cells | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | Terminated | USA | 0 |
NCT01657682 | Phase II | Crenolanib | A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations | Completed | USA | 0 |
NCT01685411 | Phase 0 | Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam | Busulfan and Cyclophosphamide Followed By ALLO BMT | Terminated | USA | 0 |
NCT01687400 | Phase II | Decitabine | Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | Completed | USA | 0 |
NCT01690624 | Phase I | BI 836858 | BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse | Completed | USA | 0 |
NCT01707004 | Phase I | Cyclophosphamide Decitabine Filgrastim Fludarabine Busulfan | Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01729845 | Phase Ib/II | Cytarabine + Etoposide + Mitoxantrone Decitabine | Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes | Completed | USA | 0 |
NCT01736943 | Phase II | Bortezomib + Pegylated liposomal doxorubicin | Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia | Completed | USA | 0 |
NCT01744223 | Phase Ib/II | Rimiducid Rivogenlecleucel | Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT01746849 | Phase II | Leuprolide Cyclophosphamide Thiotepa Palifermin | Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT01773395 | Phase II | Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus | GVAX vs. Placebo for MDS/AML After Allo HSCT | Terminated | USA | 0 |
NCT01786343 | Phase II | Decitabine | Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT01794702 | Phase Ib/II | Idarubicin Clofarabine Cytarabine Decitabine | Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia | Completed | USA | 0 |
NCT01798901 | Phase I | Decitabine + REC-2282 | AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01804101 | Phase I | CPX-351 | Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01806571 | Phase II | Cytarabine + Daunorubicin Nilotinib | Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01814826 | Phase I | MLN4924 Azacitidine | Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | Completed | USA | 0 |
NCT01822015 | Phase I | Cytarabine + Idarubicin + Sirolimus | Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01823198 | Phase Ib/II | Methotrexate anti-thymocyte globulin + Busulfan + Fludarabine Tacrolimus Filgrastim | Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies | Completed | USA | 0 |
NCT01829503 | Phase II | Cytarabine + Decitabine | Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT01834248 | Phase I | Decitabine + Rasdegafusp alfa | DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01835288 | Phase II | Arsenic trioxide | Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT01838395 | Phase II | BKT140 + Cytarabine | Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients | Completed | USA | ISR | 0 |
NCT01841333 | Phase II | Glasdegib | PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant | Completed | USA | 0 |
NCT01842646 | Phase II | Glasdegib | Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | Completed | USA | 0 |
NCT01846624 | Phase II | Decitabine + Midostaurin | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT01849276 | Phase I | Cytarabine + Metformin | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Terminated | USA | 0 |
NCT01861314 | Phase I | Bortezomib + Decitabine + Sorafenib | Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT01869114 | Phase II | Azacitidine + Sirolimus | Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy | Active, not recruiting | USA | 0 |
NCT01869803 | Phase I | Gemtuzumab ozogamicin | Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia | Approved for marketing | USA | 0 |
NCT01870596 | Phase II | Cytarabine MK-8776 | Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT01876953 | Phase Ib/II | Cytarabine + Dasatinib + Idarubicin | Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT01880437 | Phase II | Cytarabine + Vismodegib | A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome | Terminated | USA | DEU | CAN | 0 |
NCT01883362 | Phase II | Midostaurin | Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML | Completed | USA | CAN | 0 |
NCT01885689 | Phase II | Clofarabine + Melphalan | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission | Active, not recruiting | USA | 0 |
NCT01885897 | Phase Ib/II | Nogapendekin alfa inbakicept | IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT | Completed | USA | 0 |
NCT01892371 | Phase Ib/II | Azacitidine + Quizartinib Cytarabine + Quizartinib | Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT01893320 | Phase Ib/II | Decitabine + Vosaroxin | Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT01898793 | Phase Ib/II | m-ceNK cells Aldesleukin + Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Nogapendekin alfa inbakicept | Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT01907815 | Phase II | Trametinib + Uprosertib | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT01915498 | Phase Ib/II | Enasidenib | Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation | Completed | USA | FRA | 0 |
NCT01926587 | Phase Ib/II | Azacitidine + Regorafenib | Oral Rigosertib in Combination With Azacitidine | Completed | USA | FRA | 0 |
NCT01943682 | Phase I | CPX-351 | Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma | Completed | USA | 0 |
NCT01961765 | Phase I | Cabozantinib | Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02003573 | Phase I | Decitabine + Volasertib | Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
NCT02010645 | Phase II | Decitabine + Eltrombopag | Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT02016729 | Phase I | Trametinib KRT-232 | A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02019069 | Phase II | CPX-351 | CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02029417 | Phase II | Cytarabine + Decitabine + Omacetaxine mepesuccinate | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02039726 | Phase III | Cytarabine + Fludarabine Cytarabine + Etoposide + Mitoxantrone Quizartinib Filgrastim + Idarubicin | (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive | Completed | USA | POL | NLD | ITA | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 5 |
NCT02046122 | Phase I | Cytarabine + Idarubicin | Adoptive Transfer of Haplo-identical DLI for AML and MDS | Completed | USA | 0 |
NCT02049801 | Phase I | Binimetinib + Cytarabine + Idarubicin | MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02057770 | Phase I | Busulfan + Cyclophosphamide + Fludarabine Tocilizumab | Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02071927 | Phase I | Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Leukemia | Completed | USA | 0 |
NCT02073838 | Phase II | Decitabine Ribavirin + Vismodegib | Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML | Completed | CAN | 0 |
NCT02078609 | Phase I | LGH447 | A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS) | Completed | USA | NLD | ITA | FRA | DEU | AUS | 1 |
NCT02083250 | Phase I | anti-thymocyte globulin Vorinostat Busulfan + Clofarabine + Fludarabine | Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia | Completed | USA | 0 |
NCT02085408 | Phase III | Clofarabine Cytarabine + Daunorubicin | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | ISR | 1 |
NCT02088541 | Phase II | Cytarabine Azacitidine Decitabine Selinexor Hydroxyurea | Selinexor (KPT-330) in Older Patients With Relapsed AML | Completed | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | 0 |
NCT02089230 | Phase Ib/II | Binimetinib | MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy | Terminated | USA | 0 |
NCT02091245 | Phase I | Selinexor | Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML | Active, not recruiting | USA | 0 |
NCT02093403 | Phase I | Decitabine + Selinexor | Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02096055 | Phase II | Cladribine Guadecitabine Idarubicin | 4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT02098967 | Phase I | RO6839921 | A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia. | Completed | USA | CAN | 0 |
NCT02109627 | Phase I | Cytarabine + Ficlatuzumab | Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML | Terminated | USA | 0 |
NCT02109744 | Phase Ib/II | Decitabine + Sirolimus Decitabine + Ribavirin | Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients | Completed | USA | 0 |
NCT02115295 | Phase II | Cladribine + Cytarabine + Idarubicin Midostaurin | Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) | Recruiting | USA | 0 |
NCT02117297 | Phase II | Gemtuzumab ozogamicin | SCT Plus Immune Therapy in Average Risk AML/MDS | Completed | USA | 0 |
NCT02121418 | Phase I | Cytarabine + Decitabine | Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm | Completed | USA | 0 |
NCT02126553 | Phase II | Lenalidomide | Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | Completed | USA | 0 |
NCT02141477 | Phase II | Decitabine + Omacetaxine mepesuccinate | Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT02141828 | Phase I | Pinometostat | A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene | Completed | USA | CAN | 0 |
NCT02143635 | Phase I | Siremadlin | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Completed | USA | NLD | FRA | ESP | DEU | 3 |
NCT02152956 | Phase Ib/II | Flotetuzumab | Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS | Terminated | USA | NLD | ITA | ISR | GBR | FRA | ESP | DEU | 0 |
NCT02159495 | Phase I | Cyclophosphamide | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT02177812 | Phase I | GSK2879552 | A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML) | Terminated | USA | CAN | AUS | 0 |
NCT02181478 | Phase I | Fludarabine Cyclophosphamide | Intra-Osseous Co-Transplant of UCB and hMSC | Completed | USA | 0 |
NCT02190695 | Phase II | Carboplatin + Decitabine Arsenic trioxide + Decitabine | A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia | Completed | USA | 0 |
NCT02193958 | Phase Ib/II | FF-10501-01 | Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies | Completed | USA | 0 |
NCT02196857 | Phase II | Azacitidine + Sorafenib | Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation | Completed | USA | 0 |
NCT02200380 | Phase II | Plerixafor CDX-301 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | Terminated | USA | 0 |
NCT02203773 | Phase I | Decitabine + Venetoclax Azacitidine + Venetoclax | Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo) | Terminated | USA | FRA | DEU | AUS | 0 |
NCT02203903 | Phase I | MultiTAA-specific T cells | Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) | Recruiting | USA | 0 |
NCT02204020 | Phase II | Azacitidine | Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS | Withdrawn | USA | 0 |
NCT02204085 | Phase Ib/II | GO-203-2C | A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT02212561 | Phase Ib/II | Selinexor Cytarabine Cytarabine + Dexamethasone + Methotrexate Fludarabine | Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02221310 | Phase II | Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin | Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS | Completed | USA | 0 |
NCT02236013 | Phase I | Cytarabine + Idarubicin Gilteritinib | A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02238522 | Phase I | Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML | Withdrawn | USA | 0 | |
NCT02250937 | Phase II | Cladribine Busulfan Busulfan + Venetoclax Fludarabine | Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT02257138 | Phase Ib/II | Decitabine + Ruxolitinib | Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT02267863 | Phase I | APTO-253 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | Terminated | USA | 0 |
NCT02269579 | Phase II | CPX-351 | Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment | Withdrawn | USA | 0 |
NCT02270463 | Phase Ib/II | Tagraxofusp-erzs | SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission | Terminated | USA | 0 |
NCT02270788 | Phase I | Cytarabine + Leucovorin + Methotrexate Crenolanib + Sorafenib | Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies | Completed | USA | 0 |
NCT02273102 | Phase I | Tranylcypromine + Tretinoin | Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) | Completed | USA | 0 |
NCT02275533 | Phase II | Nivolumab | Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy | Active, not recruiting | USA | CAN | 0 |
NCT02283177 | Phase II | Crenolanib + Cytarabine + Daunorubicin | A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations | Completed | USA | 0 |
NCT02286726 | Phase II | CPX-351 | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02287233 | Phase I | Cytarabine + Venetoclax | A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML) | Completed | USA | ITA | DEU | AUS | 0 |
NCT02296242 | Phase Ib/II | Ulixertinib | Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes | Completed | USA | 0 |
NCT02299518 | Phase I | Etoposide Selinexor Cytarabine + Etoposide + Mitoxantrone | Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02305563 | Phase Ib/II | Cytarabine + Ulocuplumab | An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia | Terminated | USA | ROU | ITA | ISR | CAN | BRA | 4 |
NCT02306291 | Phase Ib/II | Cytarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Uproleselan | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | Completed | USA | IRL | AUS | 0 |
NCT02308761 | Phase I | TEN-010 | A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02312102 | Phase I | Bortezomib + Lenalidomide | Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02319369 | Phase I | Milademetan | Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies | Terminated | USA | 0 |
NCT02323113 | Phase Ib/II | Mivavotinib | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | Terminated | USA | CAN | 0 |
NCT02323607 | Phase I | Cytarabine + Daunorubicin + Pacritinib Decitabine + Pacritinib | Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations | Completed | USA | 0 |
NCT02333162 | Phase I | Mycophenolate mofetil Tacrolimus Fludarabine + Melphalan | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT02335814 | Phase I | FLX925 | First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02343939 | Phase Ib/II | Decitabine Cytarabine + Daunorubicin Entospletinib | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML) | Terminated | USA | DEU | CAN | 0 |
NCT02348489 | Phase III | Guadecitabine Cytarabine Azacitidine Decitabine | SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction | Completed | USA | SWE | ROU | POL | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BGR | BEL | AUT | AUS | 5 |
NCT02351037 | Phase II | Ibrutinib Cytarabine | A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02356159 | Phase Ib/II | Cytarabine + Fludarabine Palifermin Prednisone Filgrastim Methotrexate + Sirolimus + Tacrolimus Doxorubicin + Etoposide + Fludarabine + Vincristine Sulfate Cyclophosphamide + Fludarabine Rituximab | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation | Active, not recruiting | USA | 0 |
NCT02367456 | Phase Ib/II | Azacitidine + Glasdegib | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients | Completed | USA | GBR | FRA | DEU | CAN | BEL | 0 |
NCT02381548 | Phase I | Adavosertib + Belinostat | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02391480 | Phase I | Mivebresib | A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | Completed | USA | 0 |
NCT02397720 | Phase II | Azacitidine + Nivolumab | A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02400255 | Phase II | Crenolanib | Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients | Completed | USA | 0 |
NCT02400281 | Phase Ib/II | Azacitidine Crenolanib Cytarabine + Idarubicin | Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients | Completed | USA | 0 |
NCT02403310 | Phase I | Cytarabine + Daunorubicin Selinexor | A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML | Completed | USA | 0 |
NCT02412475 | Phase I | Cytarabine Sorafenib Vorinostat Filgrastim Daunorubicin Fludarabine Decitabine | Epigenetic Reprogramming in Relapse AML | Terminated | USA | 0 |
NCT02416388 | Phase II | Cytarabine + Daunorubicin Cytarabine + Vosaroxin Cytarabine Methotrexate + Mycophenolic Acid Cyclosporine + Mycophenolic Acid Cytarabine + Venetoclax Cytarabine + Dexamethasone Cyclosporine Cytarabine + Idarubicin | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1) | Recruiting | FRA | 0 |
NCT02416908 | Phase Ib/II | Selinexor Cladribine + Cytarabine + Plerixafor | Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02418000 | Phase Ib/II | E6201 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation | Terminated | USA | 0 |
NCT02421939 | Phase III | Cytarabine Cytarabine + Fludarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Azacitidine Gilteritinib Filgrastim | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Active, not recruiting | USA | TUR | POL | ITA | ISR | GBR | FRA | ESP | DEU | CAN | BEL | 3 |
NCT02464657 | Phase Ib/II | Dexamethasone Cytarabine + Idarubicin + Nivolumab | Nivolumab in Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT02472145 | Phase III | Decitabine Decitabine + Talacotuzumab | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | Completed | USA | TUR | SWE | POL | ISR | GBR | FRA | ESP | DEU | BEL | AUS | 3 |
NCT02485535 | Phase I | Selinexor | Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant | Completed | USA | 0 |
NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
NCT02488408 | Phase I | Cytarabine Bemcentinib | Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML | Unknown status | USA | NOR | ITA | DEU | 0 |
NCT02494167 | Phase I | MultiTAA-specific T cells | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | Recruiting | USA | 0 |
NCT02498665 | Phase I | DSP-7888 | A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies | Completed | USA | 0 |
NCT02520011 | Phase II | Alvocidib Cytarabine + Mitoxantrone | Alvocidib Biomarker-driven Phase 2 AML Study | Terminated | USA | GBR | ESP | CAN | 0 |
NCT02520427 | Phase I | AMG 330 | A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | NLD | DEU | CAN | 0 |
NCT02521493 | Phase III | Etoposide Thioguanine Cytarabine Asparaginase Erwinia chrysanthemi mitoxantrone hydrochloride Daunorubicin Asparaginase | Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome | Active, not recruiting | USA | NZL | CAN | AUS | 2 |
NCT02527174 | Phase I | Cytarabine + Idarubicin + Volasertib | A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC) | Withdrawn | CAN | 0 |
NCT02528877 | Phase I | Fludarabine + Melphalan Ruxolitinib + Sirolimus + Tacrolimus | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis | Withdrawn | USA | 0 |
NCT02530034 | Phase I | Hu8F4 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT02530476 | Phase Ib/II | Selinexor + Sorafenib | Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02532010 | Phase II | Decitabine + Pacritinib Cytarabine + Pacritinib | Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML | Terminated | USA | 0 |
NCT02532231 | Phase II | Nivolumab | Nivolumab in AML in Remission at High Risk for Relapse | Completed | USA | 0 |
NCT02533115 | Expanded access | CPX-351 | EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML | Approved for marketing | USA | 0 |
NCT02543879 | Phase I | FT-1101 Azacitidine + FT-1101 | Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT02545283 | Phase III | Cytarabine Cytarabine + Idasanutlin | A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | NZL | NOR | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BEL | AUT | AUS | 3 |
NCT02560025 | Phase II | Alisertib Daunorubicin Idarubicin Cytarabine | Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML | Completed | USA | 0 |
NCT02561455 | Phase Ib/II | Gilteritinib | Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial | Completed | USA | 0 |
NCT02573363 | Phase I | Cytarabine Mitoxantrone Selinexor | Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02576301 | Phase Ib/II | Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine | Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS | Unknown status | USA | 0 |
NCT02577406 | Phase III | Azacitidine Cytarabine Enasidenib | An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY) | Completed | USA | TUR | ITA | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 4 |
NCT02582359 | Phase I | Cytarabine + Daunorubicin + Ixazomib | MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age | Completed | USA | 0 |
NCT02583893 | Phase II | Cytarabine + Etoposide + Mitoxantrone + Sirolimus | Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02610777 | Phase II | Azacitidine MLN4924 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | Completed | USA | NLD | ITA | ISR | IRL | FRA | ESP | DEU | CZE | CAN | BGR | BEL | 0 |
NCT02624570 | Phase I | Midostaurin | Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy. | No longer available | USA | 0 |
NCT02626338 | Phase Ib/II | Crenolanib + Cytarabine + Mitoxantrone | Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML | Completed | USA | 0 |
NCT02632708 | Phase I | Enasidenib + Etoposide + Mitoxantrone Cytarabine + Enasidenib Cytarabine + Idarubicin + Ivosidenib Cytarabine + Daunorubicin + Enasidenib Cytarabine + Enasidenib + Idarubicin Etoposide + Ivosidenib + Mitoxantrone Cytarabine + Ivosidenib Cytarabine + Daunorubicin + Ivosidenib | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | Active, not recruiting | USA | NLD | DEU | 0 |
NCT02632721 | Phase II | BI 836858 + Decitabine Decitabine | A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) | Completed | USA | ITA | ESP | DEU | 0 |
NCT02634827 | Phase II | Decitabine + Midostaurin | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation | Terminated | USA | 0 |
NCT02635074 | Phase I | Cytarabine + Ibrutinib + Idarubicin | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02641002 | Phase I | CC-90002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) | Terminated | USA | 0 |
NCT02642965 | Phase Ib/II | CPX-351 + Cytarabine + Filgrastim + Fludarabine | Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | CAN | 0 |
NCT02649764 | Phase I | Cytarabine + Fludarabine + Prexasertib | LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS) | Completed | USA | 0 |
NCT02652871 | Phase I | Cytarabine + Idarubicin + LY2510924 | A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02665065 | Phase III | Fludarabine + Iomab-B | Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA) | Active, not recruiting | USA | CAN | 0 |
NCT02665143 | Phase Ib/II | Cytarabine + Idarubicin Nintedanib | A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02666950 | Phase II | Adavosertib Cytarabine | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02668653 | Phase III | Cytarabine + Daunorubicin + Idarubicin Cytarabine + Daunorubicin + Idarubicin + Quizartinib | Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) (QuANTUM-First) | Completed | USA | ROU | POL | ITA | ISR | HUN | HRV | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 10 |
NCT02670044 | Phase Ib/II | Idasanutlin + Venetoclax Cobimetinib + Venetoclax | A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy | Completed | USA | ITA | FRA | CAN | 0 |
NCT02674763 | Phase I | IMGN779 | Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02676323 | Phase Ib/II | Cytarabine + Fludarabine + Leucovorin + Panobinostat | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT02677922 | Phase Ib/II | Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | Active, not recruiting | USA | SWE | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS | 2 |
NCT02680951 | Phase I | Cytarabine + Dasatinib + Fludarabine + Idarubicin | Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT02683395 | Phase I | PLX51107 | A Study of PLX51107 in Advanced Malignancies | Terminated | USA | 0 |
NCT02684162 | Phase II | Guadecitabine | SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) | Completed | USA | 0 |
NCT02698189 | Phase I | Birabresib | A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005) | Terminated | 0 | |
NCT02708641 | Phase II | Pembrolizumab | A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML | Completed | USA | 0 |
NCT02715011 | Phase I | JNJ-63709178 | Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Completed | USA | ESP | 0 |
NCT02717884 | Phase Ib/II | Cytarabine + Tranylcypromine + Tretinoin | Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA) | Unknown status | DEU | 0 |
NCT02719574 | Phase I | Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib | Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation | Completed | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT02721875 | Phase I | Azacitidine Volasertib | Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes | Terminated | 1 | |
NCT02723435 | Phase II | Midostaurin | Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant | Withdrawn | 0 | |
NCT02724163 | Phase III | Gemtuzumab ozogamicin Busulfan + Fludarabine Cytarabine Cytarabine + Fludarabine Cytarabine + Daunoxome Busulfan + Cyclophosphamide Cytarabine + Mitoxantrone | International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01) | Recruiting | NZL | IRL | GBR | FRA | CHE | AUS | 0 |
NCT02727803 | Phase II | anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells | Personalized NK Cell Therapy in CBT | Recruiting | USA | 0 |
NCT02728050 | Phase Ib/II | Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone | Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02730312 | Phase I | Vibecotamab | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | Completed | USA | 0 |
NCT02743611 | Phase I | Rimiducid BPX-701 | Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms | Terminated | USA | 0 |
NCT02749708 | Phase Ib/II | IRX5183 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT02752035 | Phase II | Gilteritinib Azacitidine + Gilteritinib Azacitidine | A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 3 |
NCT02756572 | Phase I | Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine | Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02756962 | Phase II | Midostaurin Cytarabine | Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance | Active, not recruiting | USA | 0 |
NCT02768792 | Phase II | Pembrolizumab | High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML | Completed | USA | 0 |
NCT02771197 | Phase II | Fludarabine + Melphalan Pembrolizumab | Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant | Completed | USA | 0 |
NCT02775903 | Phase II | Azacitidine Azacitidine + Durvalumab | An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML) | Completed | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | 1 |
NCT02779283 | Phase I | Dasatinib Nilotinib Ponatinib Sorafenib Cytarabine + Idarubicin Sunitinib | Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02781883 | Phase II | BP1001 + Cytarabine | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With LDAC in Patients With Previously Untreated AML | Recruiting | USA | 0 |
NCT02782546 | Phase II | Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation | Recruiting | USA | 0 | |
NCT02790515 | Phase II | Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim | Provision of TCRgammadelta T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | Active, not recruiting | USA | 0 |
NCT02791919 | Phase I | Adavosertib Cytarabine + Filgrastim + Fludarabine | Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT02793544 | Phase II | Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine | HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide | Completed | USA | 0 |
NCT02795520 | Phase Ib/II | OTS167 | Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia | Terminated | USA | 0 |
NCT02802267 | Phase II | Decitabine + Inecalcitol Decitabine | Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy | Unknown status | USA | FRA | 0 |
NCT02807558 | Phase II | Azacitidine + Tamibarotene Tamibarotene | A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | FRA | 0 |
NCT02829840 | Phase Ib/II | Azacitidine + Ponatinib | Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) | Withdrawn | 0 | |
NCT02835222 | Phase II | Cytarabine + Daunorubicin + Selinexor | Selinexor With Induction, Consolidation, and Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT02835729 | Phase Ib/II | Cytarabine + Idarubicin Cytarabine + Idarubicin + Indoximod | A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02841540 | Phase I | H3B-8800 | A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia | Terminated | USA | ITA | FRA | ESP | BEL | 2 |
NCT02845297 | Phase II | Azacitidine + Pembrolizumab | Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients | Completed | USA | 0 |
NCT02846376 | Phase I | Ipilimumab Ipilimumab + Nivolumab Nivolumab | Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) | Terminated | USA | 0 |
NCT02848001 | Phase I | CC-90009 | A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes | Terminated | USA | NOR | GBR | FRA | ESP | CAN | 0 |
NCT02848248 | Phase I | SGN-CD123A | A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02864290 | Phase I | AGS62P1 | A Study to Evaluate Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML) | Terminated | USA | CAN | 0 |
NCT02878785 | Phase Ib/II | Decitabine + Talazoparib | Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) | Completed | USA | 0 |
NCT02882321 | Phase I | IACS-010759 | Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
NCT02890329 | Phase I | Decitabine + Ipilimumab | Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT02890758 | Phase I | Nogapendekin alfa inbakicept | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | Completed | USA | 0 |
NCT02892318 | Phase I | Atezolizumab + Guadecitabine | A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT02905994 | Phase I | Cytarabine + Idarubicin + Volasertib | Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia | Withdrawn | USA | 0 |
NCT02909972 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT02920008 | Phase III | Decitabine Azacitidine Cytarabine Guadecitabine | Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia | Completed | USA | SWE | POL | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BEL | 3 |
NCT02923986 | Phase Ib/II | BP1001 + Dasatinib | Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS | Withdrawn | USA | 0 |
NCT02927262 | Phase III | Gilteritinib | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | Completed | USA | SWE | ROU | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CAN | BRA | 5 |
NCT02930109 | Phase Ib/II | Cytarabine + Triciribine | A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia | Completed | USA | 0 |
NCT02931110 | Phase I | CBL0137 | Study of IV CBL0137 in Previously Treated Hematological Subjects | Terminated | USA | 0 |
NCT02936752 | Phase I | Entinostat + Pembrolizumab | Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure | Active, not recruiting | USA | 0 |
NCT02953561 | Phase Ib/II | Avelumab + Azacitidine | Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
NCT02954653 | Phase I | PF-06747143 Cytarabine + Daunorubicin + PF-06747143 Azacitidine + Decitabine + PF-06747143 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT02960646 | Phase I | Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | Completed | USA | 0 |
NCT02979366 | Phase I | MIK665 | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | Completed | USA | FRA | ESP | AUS | 0 |
NCT02981914 | Phase 0 | Pembrolizumab | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT02989844 | Phase II | Nogapendekin alfa inbakicept | QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT | Completed | USA | 0 |
NCT02993523 | Phase III | Azacitidine + Venetoclax Azacitidine | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy | Active, not recruiting | USA | TUR | SWE | POL | NOR | ITA | ISR | HUN | HRV | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | 9 |
NCT02996474 | Phase Ib/II | Decitabine + Pembrolizumab | Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT02997202 | Phase III | Gilteritinib | A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML) | Completed | USA | POL | NZL | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | 3 |
NCT03008187 | Phase Ib/II | SEL24-B489 | SEL24 in Patients With AML | Completed | USA | POL | ITA | ESP | 0 |
NCT03009240 | Phase I | Decitabine + MLN4924 | Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03013998 | Phase Ib/II | Azacitidine + Enasidenib Azacitidine + Entospletinib Cytarabine + Daunorubicin + Samalizumab Azacitidine + BI 836858 | Study of Biomarker-Based Treatment of Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03017820 | Phase I | VSV-hIFNbeta-NIS | VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma | Recruiting | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03038230 | Phase I | MCLA-117 | MCLA-117 in Acute Myelogenous Leukemia | Unknown status | USA | NLD | ITA | FRA | BEL | 0 |
NCT03041688 | Phase I | Decitabine + KRT-232 + Venetoclax | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03042689 | Phase I | Regorafenib | Study of Regorafenib in Patients With Advanced Myeloid Malignancies | Completed | USA | 0 |
NCT03050216 | Phase II | Cyclophosphamide + Fludarabine + Nogapendekin alfa inbakicept | Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML | Completed | USA | 0 |
NCT03055286 | Phase Ib/II | CWP232291 + Cytarabine | Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Unknown status | USA | 1 |
NCT03059485 | Phase II | DC AML Vaccine DC AML Vaccine + Durvalumab | DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission | Completed | USA | 0 |
NCT03063203 | Phase II | Decitabine | Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03063944 | Phase I | Decitabine + OPB-111077 | STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy | Completed | USA | 0 |
NCT03066648 | Phase I | Decitabine + Spartalizumab Decitabine + Sabatolimab + Spartalizumab Decitabine + Sabatolimab | Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | Completed | USA | NLD | GBR | FRA | FIN | ESP | DEU | AUS | 0 |
NCT03067571 | Phase II | Daratumumab | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Terminated | USA | 0 |
NCT03069352 | Phase III | Cytarabine + Venetoclax Cytarabine | A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | Active, not recruiting | USA | NZL | NOR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 8 |
NCT03069469 | Phase I | Vimseltinib | Study of DCC-3014 in Patients With Advanced Malignancies | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT03070093 | Expanded access | Gilteritinib | Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | Approved for marketing | USA | CAN | 1 |
NCT03071276 | Phase II | Cytarabine + Fludarabine + Methotrexate + Prednisone + Selinexor | Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03072043 | Phase Ib/II | APR-246 + Azacitidine | Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms | Completed | USA | 0 |
NCT03081780 | Phase I | FATE-NK100 | Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML | Completed | USA | 0 |
NCT03082209 | Phase I | ABBV-621 | A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies | Completed | USA | NLD | ESP | 1 |
NCT03092674 | Phase II | Cytarabine + Decitabine Azacitidine + Midostaurin Decitabine Azacitidine + Nivolumab Azacitidine | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03106428 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | Completed | USA | FRA | 1 |
NCT03110354 | Phase I | DS-3201b | DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) | Terminated | USA | 0 |
NCT03113643 | Phase I | Azacitidine + Tagraxofusp-erzs + Venetoclax Azacitidine + Tagraxofusp-erzs | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Recruiting | USA | 0 |
NCT03114228 | Expanded access | Midostaurin | An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) | No longer available | CAN | 0 |
NCT03125239 | Phase I | LY2874455 + Merestinib | Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03127735 | Phase I | BAY1436032 | BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) | Completed | USA | DEU | 0 |
NCT03128034 | Phase Ib/II | Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Suspended | USA | 0 |
NCT03132454 | Phase I | Decitabine + Palbociclib Dexamethasone + Palbociclib Palbociclib Palbociclib + Sorafenib | Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias | Active, not recruiting | USA | 0 |
NCT03144245 | Phase I | AMV-564 | Study of AMV564 in Patients With AML | Completed | USA | 0 |
NCT03151408 | Phase III | Azacitidine Azacitidine + Pracinostat | An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia | Terminated | USA | ROU | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | BRA | AUT | AUS | ARG | 2 |
NCT03154827 | Phase Ib/II | Atezolizumab + BKT140 | A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study | Terminated | USA | SVK | POL | ISR | ESP | CZE | 0 |
NCT03164057 | Phase II | Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03173248 | Phase III | Azacitidine Azacitidine + Ivosidenib | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE) | Active, not recruiting | USA | POL | NLD | ITA | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUT | AUS | 6 |
NCT03176277 | Phase I | ONO-7475 | A Study of ONO-7475 in Patients With Acute Leukemias | Terminated | USA | 0 |
NCT03187288 | Phase I | CFI-400945 | A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | CAN | 0 |
NCT03190278 | Phase I | UCART123 | Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03194685 | Phase Ib/II | FF-10101 | Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03194932 | Phase I | Cytarabine | Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03207334 | Phase II | Cytarabine + Midostaurin | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001) | Withdrawn | USA | 0 |
NCT03214562 | Phase Ib/II | Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax | Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT03214666 | Phase Ib/II | GTB-3550 TriKE | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | Terminated | USA | 0 |
NCT03217838 | Phase Ib/II | AZD2811 | Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients. | Terminated | USA | AUS | 0 |
NCT03224819 | Phase I | AMG 673 | Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | DEU | AUS | 0 |
NCT03226418 | Phase II | Cytarabine Decitabine + Venetoclax Azacitidine + Venetoclax CPX-351 Cytarabine + Idarubicin Azacitidine + Glasdegib Decitabine + Glasdegib | Cytarabine, Idarubicin, Liposome-encapsulated Daunorubicin-Cytarabine or Decitabine in Treating Older Patients With Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03247088 | Phase Ib/II | Busulfan + Fludarabine + Sorafenib Cyclophosphamide Tacrolimus Filgrastim | Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation | Active, not recruiting | USA | 0 |
NCT03248479 | Phase I | Azacitidine + Hu5F9-G4 Hu5F9-G4 | Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies | Terminated | USA | GBR | 0 |
NCT03250338 | Phase III | Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone Crenolanib + Cytarabine + Filgrastim + Fludarabine + Idarubicin + Mitoxantrone | Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML | Unknown status | USA | ITA | FRA | ESP | DEU | CAN | 0 |
NCT03263637 | Phase I | AZD4573 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | Completed | NLD | GBR | DEU | 0 |
NCT03263936 | Phase I | Vorinostat Decitabine Cytarabine Fludarabine Filgrastim | Epigenetic Reprogramming in Relapse/Refractory AML | Completed | USA | CAN | AUS | 0 |
NCT03267186 | Phase II | Ibrutinib | Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant | Completed | USA | 0 |
NCT03286114 | Phase I | Pembrolizumab | Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab | Terminated | USA | 0 |
NCT03286530 | Phase II | Ruxolitinib | Ruxolitinib + Allogeneic Stem Cell Transplantation in AML | Recruiting | USA | 0 |
NCT03289910 | Phase II | Carboplatin + Topotecan + Veliparib Carboplatin + Topotecan | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | Active, not recruiting | USA | 0 |
NCT03291353 | Phase 0 | Pembrolizumab | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia | Withdrawn | USA | 0 |
NCT03298516 | Phase I | DCLL9718S Azacitidine + DCLL9718S | A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy | Completed | USA | CAN | 0 |
NCT03298984 | Phase I | Alvocidib + Cytarabine + Daunorubicin | Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML). | Completed | USA | 0 |
NCT03303339 | Phase Ib/II | Decitabine + Onvansertib Cytarabine + Decitabine + Onvansertib Cytarabine + Onvansertib | PCM-075 in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML). | Completed | USA | 0 |
NCT03306264 | Phase III | Decitabine Decitabine and Cedazuridine | Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML | Completed | USA | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | AUT | 0 |
NCT03315039 | Phase Ib/II | Liposomal Annamycin | Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT03326921 | Phase I | Fludarabine HA-1 TCR T cells | HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant | Suspended | USA | 0 |
NCT03330821 | Phase Ib/II | Cytarabine + Idarubicin + MLN4924 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03335267 | Phase II | CPX-351 | Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03358719 | Phase I | Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03360006 | Phase I | ABBV-744 | A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer | Terminated | USA | 0 |
NCT03365661 | Phase II | Nogapendekin alfa inbakicept | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | Withdrawn | USA | 0 |
NCT03374332 | Phase II | Gemtuzumab ozogamicin | Infusional Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03386513 | Phase Ib/II | IMGN632 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03390296 | Phase II | Avelumab + Azacitidine + PF-04518600 Azacitidine + PF-04518600 Avelumab + Utomilumab Avelumab + Glasdegib Gemtuzumab ozogamicin + Glasdegib PF-04518600 Avelumab + PF-04518600 PF-04518600 + Utomilumab | Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1 | Completed | USA | 0 |
NCT03393611 | Phase I | anti-thymocyte globulin + Fludarabine + Melphalan CPX-351 | CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT03395873 | Phase I | Avelumab + Decitabine | Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy | Terminated | USA | 0 |
NCT03397173 | Phase II | Azacitidine + Vitamin C | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid | Completed | USA | 0 |
NCT03404193 | Phase II | Decitabine + Venetoclax | Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03404726 | Phase I | BAY2402234 | A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies | Terminated | USA | FRA | 0 |
NCT03412292 | Phase I | MAX-40279 | MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML) | Unknown status | AUS | 0 |
NCT03416179 | Phase III | Cytarabine Cytarabine + Daunorubicin + Glasdegib Azacitidine + Glasdegib Azacitidine Cytarabine + Daunorubicin | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia (BRIGHT AML1019) | Completed | USA | SWE | ROU | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 6 |
NCT03417154 | Phase II | Cyclophosphamide + Nivolumab | Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS | Completed | USA | 0 |
NCT03426605 | Phase I | LAM-003 | A Study of LAM-003 in Patients With Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03441555 | Phase I | Alvocidib + Venetoclax | A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Completed | USA | GBR | DEU | 0 |
NCT03451084 | Phase II | ASLAN003 | A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia | Completed | USA | AUS | 1 |
NCT03455504 | Phase II | Venetoclax | Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia (V-FIRST) | Active, not recruiting | ITA | 0 |
NCT03459859 | Phase I | Cytarabine + MLN4924 | Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS | Completed | USA | 0 |
NCT03465540 | Phase I | AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | Terminated | USA | ITA | GRC | FRA | AUS | 1 |
NCT03466294 | Phase II | Azacitidine + Venetoclax | Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML | Active, not recruiting | USA | 0 |
NCT03471260 | Phase Ib/II | Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | Recruiting | USA | 0 |
NCT03480360 | Phase III | Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | Active, not recruiting | USA | 0 |
NCT03483324 | Phase I | AB-110 | Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation | Completed | USA | 0 |
NCT03484520 | Phase I | Dinaciclib + Venetoclax | A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | ESP | AUS | 0 |
NCT03503409 | Phase II | Ivosidenib | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | Active, not recruiting | ITA | FRA | 0 |
NCT03503968 | Phase Ib/II | MDG1011 | TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms | Terminated | DEU | 0 |
NCT03504410 | Phase III | Cytarabine + Mitoxantrone CPI-613 + Cytarabine + Mitoxantrone | Study Evaluating Efficacy and Safety of CPI-613 in Combination With HD Cytarabine and Mitoxantrone vs HD Cytarabine and Mitoxantrone in Older Patients With R/R AML | Terminated | USA | POL | FRA | ESP | DEU | BEL | AUT | AUS | 1 |
NCT03512197 | Phase III | Daunorubicin + Midostaurin Cytarabine + Idarubicin + Midostaurin Cytarabine + Idarubicin Daunorubicin | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | Completed | USA | TUR | POL | NOR | ITA | ISR | FRA | ESP | DEU | CZE | CHE | BRA | BGR | BEL | AUT | AUS | ARG | 3 |
NCT03513484 | Phase I | Azacitidine + Nintedanib | Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03515512 | Phase I | Enasidenib | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT03526926 | FDA approved | CPX-351 | A Post-Marketing Observational Study of VYXEOS | Completed | USA | 0 |
NCT03531736 | Phase I | Rituximab Cyclophosphamide + Fludarabine | T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia | Active, not recruiting | USA | 0 |
NCT03531918 | Phase Ib/II | Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin + Mitoxantrone Cladribine + Cytarabine + Filgrastim | Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm | Completed | USA | 0 |
NCT03537482 | Phase I | APG-2575 | APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT03537599 | Phase Ib/II | Daratumumab | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant | Completed | USA | 0 |
NCT03541369 | Phase I | AMG 427 | Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (20170528) | Terminated | USA | DEU | CAN | AUS | 2 |
NCT03552029 | Phase I | Milademetan + Quizartinib | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03557970 | Phase II | Edicotinib | CSF1R Inhibitor JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03560882 | Phase I | Atorvastatin | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | Active, not recruiting | USA | 0 |
NCT03564288 | Phase I | SKI-G-801 | Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT03564821 | Phase I | Ivosidenib | IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | Completed | USA | 0 |
NCT03568994 | Phase I | Atovaquone + Cytarabine + Daunorubicin + Etoposide Atovaquone + Cytarabine + Daunorubicin + Gemtuzumab ozogamicin | Atovaquone (Mepron) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | 0 |
NCT03573024 | Phase II | Venetoclax Azacitidine | Venetoclax and Azacitidine for Non-Elderly Adult Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03586609 | Phase II | Azacitidine + Cladribine + Cytarabine + Venetoclax | Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Participants With Patients Previously Untreated Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03591510 | Phase II | Cytarabine Cytarabine + Etoposide Cytarabine + Mitoxantrone Cytarabine + Fludarabine + Idarubicin Cytarabine + Daunorubicin + Fludarabine Cytarabine + Daunoxome + Fludarabine Midostaurin | A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML | Recruiting | USA | TUR | SVN | POL | ITA | GRC | DEU | CZE | AUT | 4 |
NCT03594955 | Phase Ib/II | SAR440234 | First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome | Terminated | USA | FRA | 0 |
NCT03600155 | Phase I | Nivolumab Ipilimumab Ipilimumab + Nivolumab | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Participants With High Risk Refractory or Relapsed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03603964 | Phase II | Guadecitabine | Guadecitabine Extension Study | Terminated | USA | ITA | ESP | DNK | CAN | AUT | 3 |
NCT03613532 | Phase I | Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine | Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN | Recruiting | USA | 0 |
NCT03614728 | Phase I | Azacitidine + GSK3326595 GSK3326595 | Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | Terminated | USA | CAN | 0 |
NCT03616470 | Phase III | Cytarabine + Etoposide + Mitoxantrone + Uproleselan Cytarabine + Fludarabine + Idarubicin + Uproleselan Cytarabine + Etoposide + Mitoxantrone Cytarabine + Fludarabine + Idarubicin | Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | NLD | ITA | IRL | GBR | FRA | ESP | CAN | AUS | 0 |
NCT03625505 | Phase I | Gilteritinib + Venetoclax | A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03629171 | Phase II | CPX-351 + Venetoclax | Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03634228 | Phase Ib/II | Cytarabine + Milademetan Cytarabine + Milademetan + Venetoclax | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03661307 | Phase Ib/II | Decitabine + Quizartinib + Venetoclax | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03670966 | Phase Ib/II | BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus | 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome | Suspended | USA | 0 |
NCT03672539 | Phase I | Gemtuzumab ozogamicin CPX-351 + Gemtuzumab ozogamicin | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT03674411 | Phase II | Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Active, not recruiting | USA | 0 |
NCT03683433 | Phase II | Azacitidine + Enasidenib | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | Recruiting | USA | 0 |
NCT03690115 | Phase II | Ponatinib | Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients (PONALLO) | Active, not recruiting | FRA | 0 |
NCT03699384 | Phase Ib/II | Avelumab + Azacitidine | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) | Withdrawn | USA | 0 |
NCT03699475 | Phase II | Rimiducid + Rivogenlecleucel Cyclophosphamide | Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE) | Terminated | USA | 0 |
NCT03701295 | Phase Ib/II | Azacitidine + Pinometostat | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | Completed | USA | 0 |
NCT03701308 | Phase II | Cytarabine + Daunorubicin Cytarabine + Uproleselan Cytarabine + Daunorubicin + Uproleselan Cytarabine | Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | Active, not recruiting | USA | 0 |
NCT03709576 | Phase II | Azacitidine + MLN4924 | Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML | Terminated | USA | 0 |
NCT03709758 | Phase I | Cytarabine + Daunorubicin + Venetoclax | Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naive AML | Recruiting | USA | 0 |
NCT03724084 | Phase Ib/II | Cytarabine + Daunorubicin + Pinometostat | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | Terminated | USA | 0 |
NCT03728335 | Phase I | Enasidenib | Enasidenib as Maintenance Therapy in Treating Patients With Acute Myeloid Leukemia With IDH2 Mutation After Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT03730012 | Phase Ib/II | Atezolizumab + Gilteritinib | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | Completed | USA | 0 |
NCT03735446 | Phase I | Cytarabine + Etoposide + Mitoxantrone + Prexasertib | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | Terminated | USA | 0 |
NCT03735875 | Phase Ib/II | Quizartinib + Venetoclax | Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03737955 | Phase II | Gemtuzumab ozogamicin | Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Participants With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03745352 | Phase II | Azacitidine Azacitidine + MLN4924 | Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT03752138 | Phase I | Decitabine + TK216 TK216 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT03755154 | Phase I | VOB560 | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia | Terminated | GBR | FRA | ESP | AUS | 0 |
NCT03760523 | Phase I | Minnelide | Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03760666 | Phase Ib/II | Brequinar | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03761069 | Phase I | PTC299 | Study of PTC299 in Relapsed/Refractory Acute Leukemias | Terminated | USA | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Completed | USA | 0 |
NCT03772925 | Phase I | Belinostat + MLN4924 | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Active, not recruiting | USA | 0 |
NCT03787498 | Phase I | PLX2853 | A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT03793478 | Phase Ib/II | Etoposide Cytarabine + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Methotrexate + Prednisolone + Quizartinib Cytarabine + Daunorubicin + Fludarabine + Hydrocortisone + Methotrexate + Quizartinib Cytarabine + Fludarabine + Methotrexate + Prednisolone Quizartinib | Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | Active, not recruiting | USA | SWE | NLD | ITA | ISR | FRA | ESP | DNK | CAN | BEL | 0 |
NCT03797261 | Phase I | AMG 176 + Venetoclax | A Study of Venetoclax and AMG 176 in Patients With Relapsed/Refractory Hematologic Malignancies | Terminated | USA | DEU | AUS | 0 |
NCT03807063 | Phase I | Rimiducid Rivogenlecleucel | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Withdrawn | USA | 0 |
NCT03813147 | Phase I | Azacitidine + Cytarabine + Fludarabine + MLN4924 Cytarabine Cytarabine + Hydrocortisone + Methotrexate | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT03816319 | Phase I | TAK-243 | TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts | Recruiting | USA | 0 |
NCT03825796 | Phase II | CPX-351 + Enasidenib Cytarabine + Enasidenib Enasidenib | CPX-351 Plus Enasidenib for Relapsed AML | Active, not recruiting | USA | 0 |
NCT03826992 | Phase I | CPX-351 + Venetoclax | Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia | Recruiting | USA | 0 |
NCT03833180 | Phase I | VLS-101 | A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies | Completed | USA | 0 |
NCT03836209 | Phase II | Cytarabine + Daunorubicin + Gilteritinib Cytarabine + Daunorubicin + Midostaurin Cytarabine Midostaurin | Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03839446 | Phase II | Etoposide + Gemtuzumab ozogamicin + Mitoxantrone | Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | Active, not recruiting | USA | 0 |
NCT03839771 | Phase III | Ivosidenib Enasidenib | A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) | Active, not recruiting | SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | EST | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT03843528 | Phase I | Azacitidine + Vorinostat | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | Recruiting | USA | 0 |
NCT03844815 | Phase I | Decitabine + Venetoclax | Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03844997 | Phase I | CPX-351 + Palbociclib | Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03848754 | Phase I | Gemtuzumab ozogamicin + Pracinostat | Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT03850535 | Phase Ib/II | Cytarabine + Idasanutlin Cytarabine + Daunorubicin + Idasanutlin Idasanutlin | A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission | Terminated | USA | ITA | FRA | ESP | AUS | 0 |
NCT03850574 | Phase Ib/II | Tuspetinib + Venetoclax Tuspetinib | Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (APTIVATE) | Recruiting | USA | NZL | ESP | DEU | AUS | 1 |
NCT03860844 | Phase II | Idarubicin Cyclophosphamide Isatuximab Doxorubicin Etoposide Daunoxome Cytarabine Methotrexate Daunorubicin Fludarabine Dexamethasone Mitoxantrone Filgrastim Vincristine Sulfate Pegaspargase | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | Terminated | USA | SWE | NOR | NLD | ITA | HUN | GRC | FRA | DNK | DEU | BRA | ARG | 4 |
NCT03862157 | Phase Ib/II | Azacitidine + MLN4924 + Venetoclax | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03874052 | Phase I | Ruxolitinib + Venetoclax | Ruxolitinib in Combination With Venetoclax for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia | Suspended | USA | 0 |
NCT03878199 | Phase Ib/II | CPX-351 + Ruxolitinib | Cytarabine and Daunorubicin in Combination With Ruxolitinib for the Treatment of Secondary Acute Myeloid Leukemia Transformed From Myeloproliferative Neoplasms. | Recruiting | USA | 0 |
NCT03878524 | Phase I | Oxaliplatin Palbociclib Vemurafenib Sirolimus Tretinoin Celecoxib Ipilimumab Ruxolitinib Dasatinib Abiraterone Idelalisib Trametinib Imatinib Erlotinib Carboplatin Olaparib Panobinostat Bortezomib Afatinib Fluorouracil Vorinostat Pembrolizumab Leucovorin Enzalutamide Ponatinib Nivolumab Everolimus Sunitinib Cabazitaxel Cabozantinib Lenvatinib Pertuzumab Sorafenib Venetoclax Bevacizumab | A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (SMMART) | Terminated | USA | 0 |
NCT03878927 | Phase I | CPX-351 + Gemtuzumab ozogamicin | CPX-351+GO in Subjects 55 Years Old, or Older, With AML (CPX GO) | Terminated | USA | 0 |
NCT03881735 | Phase II | Enasidenib | Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation | Withdrawn | USA | 0 |
NCT03885947 | Phase I | Cyclophosphamide + Fludarabine + Thiotepa | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies | Completed | USA | 0 |
NCT03900949 | Phase I | Midostaurin Cytarabine Cytarabine + Gemtuzumab ozogamicin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin | Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03904069 | Phase I | Anti-FLT3 CAR-T cells | Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML | Withdrawn | USA | 0 |
NCT03904251 | Phase I | CPX-351 + Gemtuzumab ozogamicin | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03912064 | Phase I | Ipilimumab | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT | Active, not recruiting | USA | 0 |
NCT03913026 | Phase II | ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa | UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia | Active, not recruiting | CAN | 0 |
NCT03915379 | Phase I | JNJ-67571244 | A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Completed | USA | ESP | DEU | 0 |
NCT03922100 | Phase Ib/II | NMS-P088 | Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Terminated | ITA | FRA | ESP | 0 |
NCT03922477 | Phase I | Atezolizumab + Hu5F9-G4 | A Study Evaluating the Safety and Pharmacokinetics of Atezolizumab Administered in Combination With Hu5F9-G4 to Patients With Relapsed and/or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT03926624 | Phase III | Decitabine + Venetoclax Azacitidine + Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin Cytarabine + Venetoclax Cytarabine + Filgrastim + Fludarabine Decitabine Azacitidine Cladribine + Cytarabine + Filgrastim + Mitoxantrone DFP-10917 Cladribine + Cytarabine + Filgrastim + Idarubicin Cytarabine Cytarabine + Etoposide + Mitoxantrone | Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage | Unknown status | USA | 0 |
NCT03927261 | Phase I | PRGN-3006 | PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS | Active, not recruiting | USA | 0 |
NCT03931291 | Phase II | APR-246 + Azacitidine | APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant | Completed | USA | 0 |
NCT03932643 | Phase I | ONC201 | ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant | Active, not recruiting | USA | 0 |
NCT03934372 | Phase Ib/II | Ponatinib | Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors | Recruiting | SWE | NLD | ITA | GBR | FRA | ESP | DNK | DEU | BEL | 0 |
NCT03940352 | Phase I | Siremadlin + Venetoclax Sabatolimab + Siremadlin | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | Terminated | USA | ITA | FIN | ESP | DEU | AUS | 1 |
NCT03941964 | Phase III | Decitabine + Venetoclax Azacitidine + Venetoclax | A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | Completed | USA | 0 |
NCT03953898 | Phase II | Olaparib | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation | Active, not recruiting | USA | 0 |
NCT03955783 | Phase I | Selinexor + Venetoclax | Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies | Completed | USA | 0 |
NCT03957915 | Phase I | INA03 | Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia (INA03) | Recruiting | FRA | 0 |
NCT03969420 | Phase II | Alvocidib + Cytarabine Alvocidib | Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy | Terminated | USA | 0 |
NCT03969446 | Phase I | Decitabine + Pembrolizumab | Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | Recruiting | USA | 0 |
NCT03971799 | Phase Ib/II | Cyclophosphamide + Fludarabine Anti-CD33 CAR-T cells | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03974217 | Phase I | Talazoparib | Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts | Recruiting | USA | 0 |
NCT03983824 | Phase I | Cytarabine + Etoposide + Mitoxantrone + Peposertib | Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT03988205 | FDA approved | CPX-351 | Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT04013880 | Phase Ib/II | Decitabine and Cedazuridine + Olutasidenib | ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia | Withdrawn | 0 | |
NCT04021368 | Phase I | RVU120 | SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome | Active, not recruiting | USA | POL | 0 |
NCT04022785 | Phase I | Azacitidine + PLX51107 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | 0 |
NCT04023071 | Phase I | Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Obinutuzumab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 + Rituximab Aldesleukin + Cyclophosphamide + Fludarabine + FT516 | FT516 in Subjects With Advanced Hematologic Malignancies | Terminated | USA | 0 |
NCT04023526 | Phase II | ARGX-110 + Azacitidine | A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (CULMINATE) | Active, not recruiting | TUR | ITA | ISR | FRA | ESP | CHE | BRA | AUS | 1 |
NCT04027309 | Phase III | Midostaurin Gilteritinib | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) | Active, not recruiting | SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | ESP | DEU | CHE | BEL | AUT | AUS | 0 |
NCT04029688 | Phase Ib/II | Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin | A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | Completed | USA | NLD | GBR | FRA | ESP | CAN | 0 |
NCT04047641 | Phase II | Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04049539 | Phase II | CPX-351 | Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction | Recruiting | USA | 0 |
NCT04050280 | Phase II | Cladribine + Cytarabine + Filgrastim + Gemtuzumab ozogamicin Gemtuzumab ozogamicin Cladribine + Cytarabine + Filgrastim | CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | Recruiting | USA | 0 |
NCT04051996 | Phase II | Decitabine + Glasdegib | GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT04055844 | Phase II | Decitabine + Ruxolitinib | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS | Completed | USA | 0 |
NCT04062266 | Phase II | Azacitidine + Venetoclax | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | Recruiting | USA | 0 |
NCT04065399 | Phase Ib/II | Revumenib | A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) | Recruiting | USA | NLD | LTU | ITA | ISR | FRA | ESP | DEU | CAN | AUS | 1 |
NCT04067336 | Phase I | Ziftomenib | First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT04068597 | Phase Ib/II | CCS1477 | Study to Evaluate CCS1477 in Haematological Malignancies | Recruiting | USA | SWE | GBR | FRA | ESP | 0 |
NCT04070768 | Phase I | Gemtuzumab ozogamicin + Venetoclax Venetoclax | Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 | Active, not recruiting | USA | 0 |
NCT04075747 | Phase I | CPX-351 + Enasidenib CPX-351 + Venetoclax CPX-351 + Midostaurin | A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia (V-FAST) | Completed | USA | 0 |
NCT04079296 | Phase Ib/II | ASP7517 | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | Completed | USA | 1 |
NCT04079738 | Phase Ib/II | Ixazomib + Mivavotinib | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | Terminated | USA | 0 |
NCT04081259 | Phase I | LY3214996 | LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy | Recruiting | USA | 0 |
NCT04086264 | Phase Ib/II | IMGN632 IMGN632 + Venetoclax Azacitidine + IMGN632 Azacitidine + IMGN632 + Venetoclax | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
NCT04090736 | Phase III | Azacitidine Azacitidine + MLN4924 | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy (PEVOLAM) | Unknown status | ESP | 1 |
NCT04092179 | Phase Ib/II | Enasidenib + Venetoclax | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | Terminated | CAN | 0 |
NCT04093505 | Phase III | Gemtuzumab ozogamicin + Glasdegib Gemtuzumab ozogamicin | Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (GnG) | Terminated | DEU | 0 |
NCT04102020 | Phase III | Azacitidine + Venetoclax | A Safety and Efficacy Study of Oral Venetoclax Tablets and Injectable Azacitidine Versus Best Supportive Care as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy to Evaluate Improvement in Relapse-Free Survival (VIALE-M) | Active, not recruiting | USA | TUR | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | AUS | 6 |
NCT04103879 | Phase II | ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil | US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia | Active, not recruiting | USA | NLD | 0 |
NCT04107727 | Phase II | Cytarabine Cytarabine + Idarubicin Cytarabine + Idarubicin + Quizartinib Quizartinib Cytarabine + Quizartinib | Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) | Unknown status | ESP | 0 |
NCT04109482 | Phase Ib/II | Cyclophosphamide + Decitabine + Fludarabine + MB-102 | Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS. | Terminated | USA | 0 |
NCT04112589 | Phase Ib/II | Cytarabine + Fludarabine + Idarubicin + Lenograstim + Quizartinib Lenograstim | A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment | Unknown status | ESP | 0 |
NCT04113616 | Phase Ib/II | KRT-232 Decitabine + KRT-232 Cytarabine + KRT-232 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | Terminated | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT04128020 | Phase I | Azacitidine + Nivolumab Nivolumab | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia | Withdrawn | 0 | |
NCT04128501 | Phase II | Azacitidine + Venetoclax | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | Recruiting | USA | 0 |
NCT04128748 | Phase Ib/II | CPX-351 + Quizartinib | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04139434 | Phase I | LP-108 | Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | ESP | 0 |
NCT04140487 | Phase Ib/II | Azacitidine + Gilteritinib + Venetoclax | Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm | Recruiting | USA | 0 |
NCT04146038 | Phase II | Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax | Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease | Completed | USA | 0 |
NCT04150029 | Phase II | Azacitidine + Sabatolimab + Venetoclax | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy (STIMULUS-AML1) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUS | 3 |
NCT04150887 | Phase I | ARGX-110 + Azacitidine + Venetoclax ARGX-110 + Venetoclax ARGX-110 + Azacitidine | Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE) | Active, not recruiting | USA | POL | DEU | CHE | CAN | 0 |
NCT04155580 | Phase I | ASTX-660 ASTX-660 + Decitabine and Cedazuridine | A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
NCT04158739 | Phase I | Cytarabine + Flotetuzumab | Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04161885 | Phase III | Azacitidine + Venetoclax | A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) (VIALE-T) | Active, not recruiting | USA | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | AUS | 4 |
NCT04167696 | Phase I | CYAD-02 Cyclophosphamide + Fludarabine | Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) | Recruiting | USA | BEL | 0 |
NCT04167917 | Phase I | NTX-301 | NTX-301 in MDS/AML | Recruiting | USA | 0 |
NCT04168502 | Phase III | Gemtuzumab ozogamicin + Glasdegib Gemtuzumab ozogamicin | Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML | Recruiting | ITA | 0 |
NCT04172844 | Phase I | Azacitidine + MLN4924 + Venetoclax | Pevonedistat, Azacitidine, and Venetoclax for the Treatment of Patients With Acute Myelogenous Leukemia (PAVE) | Terminated | USA | 0 |
NCT04173585 | Phase II | Bortezomib + Gemtuzumab ozogamicin | TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (TEAM) | Completed | DEU | 0 |
NCT04188405 | Phase II | Decitabine + Ponatinib + Venetoclax | Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia | Active, not recruiting | USA | 0 |
NCT04190550 | Phase I | Cytarabine + Idarubicin + KRT-232 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04195945 | Phase II | CPX-351 Cladribine + Cytarabine + Filgrastim + Mitoxantrone | CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients | Recruiting | USA | 0 |
NCT04203316 | Phase II | Enasidenib | Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | Recruiting | USA | CAN | 0 |
NCT04207190 | Phase Ib/II | Gemtuzumab ozogamicin + Talazoparib | Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia | Completed | USA | 0 |
NCT04209725 | Phase II | CPX-351 + Quizartinib | A Study of CPX-351 (Vyxeos) With Quizartinib for the Treatment of FLT3-ITD Mutation-Positive Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT04214249 | Phase II | Cytarabine + Daunorubicin Cytarabine Cytarabine + Idarubicin Pembrolizumab Cytarabine + Daunorubicin + Pembrolizumab Cytarabine + Pembrolizumab Cytarabine + Idarubicin + Pembrolizumab | BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04214860 | Phase I | APR-246 + Azacitidine + Venetoclax | APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies | Completed | USA | 0 |
NCT04219163 | Phase I | CLL-1 CAR-T cells | Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen | Recruiting | USA | 0 |
NCT04227847 | Phase I | SEA-CD70 | A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Recruiting | USA | NLD | 0 |
NCT04229979 | Phase III | Galinpepimut-S Cytarabine Decitabine Venetoclax Azacitidine | Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (REGAL) | Active, not recruiting | USA | POL | HUN | GRC | FRA | ESP | DEU | 3 |
NCT04231851 | Phase II | CPX-351 + Glasdegib | CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04240002 | Phase Ib/II | Cytarabine + Filgrastim + Fludarabine + Gilteritinib | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 0 |
NCT04243499 | Phase I | ICT01 | First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) | Recruiting | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04243785 | Phase I | BTX-A51 | A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04250051 | Phase I | Cytarabine + Filgrastim + Fludarabine + Ivosidenib Ivosidenib | Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04256317 | Phase III | ASTX030 ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine | A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML | Active, not recruiting | USA | CAN | 0 |
NCT04266795 | Phase II | Azacitidine + Venetoclax Azacitidine + MLN4924 + Venetoclax | A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy (PEVENAZA) | Active, not recruiting | USA | POL | ITA | FRA | CAN | 0 |
NCT04272203 | Phase I | ABBV-184 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers | Terminated | USA | ISR | GBR | FRA | 1 |
NCT04277442 | Phase I | Decitabine + Nivolumab + Venetoclax | Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04278768 | Phase I | CA-4948 | An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome | Recruiting | USA | POL | ITA | ISR | FRA | ESP | DEU | CZE | 0 |
NCT04282668 | Phase I | TAS1440 + Tretinoin TAS1440 | A Study of TAS1440 With ATRA in Subjects With r/r AML | Active, not recruiting | USA | 0 |
NCT04284228 | Phase Ib/II | Cyclophosphamide + Fludarabine + NEXI-001 T Cells | Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT | Active, not recruiting | USA | 0 |
NCT04284787 | Phase II | Azacitidine + Pembrolizumab + Venetoclax Azacitidine + Venetoclax | BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04310592 | Phase I | Cyclophosphamide + Fludarabine CYNK-001 | Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01) | Recruiting | USA | 0 |
NCT04318678 | Phase I | Cyclophosphamide + Fludarabine + MB-102 + Mesna + Rituximab | CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML) | Recruiting | USA | 0 |
NCT04326439 | Phase II | Cytarabine + Etoposide Cytarabine + Etoposide + Sorafenib Asparaginase Erwinia chrysanthemi + Cytarabine + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Sorafenib Cytarabine + Mitoxantrone + Sorafenib Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin Asparaginase Erwinia chrysanthemi + Cytarabine Cytarabine + Mitoxantrone | AflacLL1901 (CHOA-AML) | Terminated | USA | 0 |
NCT04326764 | Phase III | Panobinostat | Panobinostat Maintenance After HSCT fo High-risk AML and MDS | Terminated | NLD | DEU | 0 |
NCT04336982 | Phase Ib/II | Azacitidine + CC-90009 + Venetoclax CC-90009 + Gilteritinib | A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia | Terminated | USA | GBR | FRA | CAN | BEL | 0 |
NCT04358393 | Phase Ib/II | Alrizomadlin + Azacitidine Alrizomadlin | A Study of APG-115 Alone or in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT04361058 | Phase I | Nivolumab | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide | Withdrawn | USA | 0 |
NCT04372433 | Phase I | Azacitidine + IO-202 IO-202 Azacitidine + IO-202 + Venetoclax | IO-202 as Monotherapy and IO-202 Plus Azacitidine +/- Venetoclax in Patients in AML and CMML | Active, not recruiting | USA | 0 |
NCT04385290 | Phase Ib/II | Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Midostaurin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin | Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC) | Recruiting | DEU | 0 |
NCT04402541 | Phase I | CB-5339 | Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | USA | AUS | 0 |
NCT04429191 | Phase I | JSP191 | JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation | Unknown status | USA | 0 |
NCT04435691 | Phase Ib/II | Azacitidine + Hu5F9-G4 + Venetoclax | Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04477291 | Phase Ib/II | CG-806 | A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04478695 | Phase I | AMG 330 + Pembrolizumab | Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT04487106 | Phase II | Azacitidine + Trametinib + Venetoclax | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | Completed | USA | 0 |
NCT04493099 | Phase Ib/II | Alvocidib + Decitabine + Venetoclax | Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML | Withdrawn | USA | 0 |
NCT04493164 | Phase II | CPX-351 + Ivosidenib Ivosidenib | CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04500587 | Phase I | ZN-d5 | Phase 1 First in Human Study of ZN-d5 as a Single Agent | Completed | POL | HRV | ESP | BGR | AUS | 2 |
NCT04511130 | Phase II | MT-401 | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant | Completed | USA | 0 |
NCT04512105 | Phase I | Azacitidine + Pitavastatin + Venetoclax Decitabine + Pitavastatin + Venetoclax Pitavastatin + Venetoclax | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04518345 | Phase Ib/II | Dubermatinib Azacitidine + Dubermatinib | TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia | Completed | USA | 0 |
NCT04522895 | Phase II | Enasidenib | IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT | Completed | DEU | 0 |
NCT04526795 | Phase I | Cytarabine + Fludarabine + Pegcrisantaspase | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia | Active, not recruiting | USA | 0 |
NCT04543305 | Phase I | PRT1419 | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies | Completed | USA | 0 |
NCT04547062 | Phase I | Tocilizumab | Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML) (Tocilam) | Completed | FRA | 0 |
NCT04580121 | Phase I | Dasatinib + RO7283420 + Tocilizumab | A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420. | Completed | USA | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUS | 1 |
NCT04581512 | Phase Ib/II | EP0042 | Study to Evaluate the Safety and Tolerability of EP0042 | Recruiting | NLD | GBR | AUS | 0 |
NCT04582864 | Phase II | Flotetuzumab | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | Terminated | USA | 0 |
NCT04588922 | Phase I | GFH009 | A Study of GFH009 in Patients With Hematologic Malignancies | Recruiting | USA | 1 |
NCT04609826 | Phase I | JNJ74856665 Azacitidine + JNJ74856665 JNJ74856665 + Venetoclax | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Active, not recruiting | GBR | FRA | ESP | 1 |
NCT04614636 | Phase I | Cyclophosphamide + Fludarabine Daratumumab + FT538 Elotuzumab + FT538 FT538 | FT538 in Subjects With Advanced Hematologic Malignancies | Terminated | USA | 0 |
NCT04623216 | Phase Ib/II | Sabatolimab Azacitidine + Sabatolimab | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. | Completed | ITA | FRA | ESP | DEU | 0 |
NCT04628026 | Phase III | Cytarabine + Idarubicin + Venetoclax Cytarabine + Idarubicin Etoposide + Mitoxantrone + Venetoclax Etoposide + Mitoxantrone Cytarabine + Venetoclax Cytarabine + Daunorubicin + Venetoclax Cytarabine + Daunorubicin | Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 | Recruiting | DEU | 0 |
NCT04629443 | Phase Ib/II | Azacitidine + MIK665 | Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia | Completed | USA | FRA | ESP | AUS | 0 |
NCT04637009 | Phase I | TAS1553 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | Terminated | USA | CAN | 0 |
NCT04639024 | Phase II | Camidanlumab tesirine | ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN | Terminated | USA | 0 |
NCT04655391 | Phase I | Glasdegib Glasdegib + Ivosidenib Bosutinib + Glasdegib Gilteritinib + Glasdegib Decitabine + Glasdegib + Venetoclax Enasidenib + Glasdegib | Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell Transplantation | Withdrawn | USA | 0 |
NCT04657081 | Phase I | Decitabine and Cedazuridine + Venetoclax | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | ESP | CAN | 0 |
NCT04659616 | Phase I | Cytarabine + Pemigatinib Cytarabine + Daunorubicin + Pemigatinib | Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04666649 | Phase I | Pegcrisantaspase + Venetoclax | Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) | Active, not recruiting | USA | 0 |
NCT04669067 | Phase Ib/II | KRT-232 + TL-895 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Active, not recruiting | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
NCT04678336 | Phase I | CART123 cells Cyclophosphamide + Fludarabine | CD123 Redirected T Cells for AML in Pediatric Subjects | Recruiting | USA | 0 |
NCT04687761 | Phase Ib/II | Cytarabine + Quizartinib + Venetoclax Azacitidine + Quizartinib + Venetoclax | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | Unknown status | ESP | 0 |
NCT04702425 | Phase I | MIK665 + VOB560 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | Terminated | USA | ITA | ISR | FIN | ESP | BEL | 3 |
NCT04708054 | Phase II | Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax | Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS | Recruiting | USA | 0 |
NCT04712942 | Phase II | Azacitidine + MLN4924 Azacitidine | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat | Completed | DEU | 0 |
NCT04714372 | Phase I | Cyclophosphamide + Fludarabine Daratumumab and hyaluronidase-fihj + FT538 | FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia | Completed | USA | 0 |
NCT04730258 | Phase Ib/II | CFI-400945 CFI-400945 + Decitabine Azacitidine + CFI-400945 | A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML (TWT-202) | Recruiting | USA | CAN | 1 |
NCT04742101 | Phase Ib/II | Azacitidine + VOB560 | Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia | Active, not recruiting | POL | HUN | GBR | FRA | ESP | 1 |
NCT04746235 | Phase II | Decitabine and Cedazuridine + Venetoclax | Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04748848 | Phase Ib/II | Azacitidine + Venetoclax Azacitidine + CC-90011 + Venetoclax | A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy | Terminated | USA | FRA | ESP | BEL | 0 |
NCT04752163 | Phase Ib/II | Cyclophosphamide + Cytarabine + Dexamethasone + DS-1594b + Filgrastim + Mesna + Methotrexate + Vincristine Sulfate DS-1594b + Prednisone + Vincristine Sulfate DS-1594b Azacitidine + DS-1594b + Venetoclax Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate Cytarabine + DS-1594b + Filgrastim + Leucovorin + Methotrexate + Rituximab | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | Completed | USA | 0 |
NCT04755244 | Phase Ib/II | Azacitidine + Evorpacept + Venetoclax | A Study of ALX148 With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | Terminated | USA | 0 |
NCT04771130 | Phase Ib/II | Azacitidine + BGB-11417 | A Study of BGB-11417 in Participants With Myeloid Malignancies | Recruiting | USA | NZL | ITA | GBR | FRA | ESP | DEU | AUS | 2 |
NCT04771572 | Phase I | LP-118 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | Recruiting | USA | 0 |
NCT04774393 | Phase Ib/II | Decitabine and Cedazuridine + Ivosidenib + Venetoclax Decitabine and Cedazuridine + Enasidenib + Venetoclax | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04778397 | Phase III | Cytarabine + Idarubicin Azacitidine + Venetoclax Azacitidine + Hu5F9-G4 Cytarabine + Daunorubicin | Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated (ENHANCE-2) | Terminated | USA | SWE | ITA | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BEL | AUT | AUS | 2 |
NCT04778410 | Phase II | Azacitidine + Hu5F9-G4 + Venetoclax Cytarabine + Etoposide + Hu5F9-G4 + Mitoxantrone Azacitidine + Hu5F9-G4 | Study of Magrolimab Combinations in Participants With Myeloid Malignancies | Completed | USA | GBR | AUS | 0 |
NCT04789408 | Phase I | Cyclophosphamide + Fludarabine + KITE-222 | Study Evaluating the Safety of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | FRA | 0 |
NCT04789655 | Phase I | CC-96191 | Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | FRA | CAN | 0 |
NCT04797767 | Phase I | Cladribine + Cytarabine + Mitoxantrone + Sargramostim + Venetoclax | Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms | Suspended | USA | 0 |
NCT04801797 | Phase II | Azacitidine + Venetoclax Cytarabine + Idarubicin Cytarabine + Daunoxome Cytarabine + Daunorubicin | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | Recruiting | USA | 0 |
NCT04817241 | Phase Ib/II | Cytarabine + Daunorubicin Decitabine and Cedazuridine + Venetoclax | Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients | Active, not recruiting | USA | 0 |
NCT04848974 | Phase Ib/II | Cladribine + Cytarabine + Uproleselan | Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia | Completed | USA | 0 |
NCT04865419 | Phase Ib/II | AZD0466 + Voriconazole AZD0466 | Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies | Terminated | USA | ITA | FRA | DEU | AUS | 1 |
NCT04872478 | Phase I | MRX-2843 | Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL | Recruiting | USA | 0 |
NCT04874194 | Phase Ib/II | Omacetaxine mepesuccinate + Venetoclax | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | Completed | USA | 0 |
NCT04874480 | Phase I | BC2059 + Decitabine | Tegavivint for the Treatment of Relapsed or Refractory Leukemia | Active, not recruiting | USA | 0 |
NCT04887857 | Phase I | Azacitidine + Venetoclax | A Study to Assess Safety and Tolerability of CC-486 (ONUREG, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (OMNIVERSE) | Completed | USA | AUS | 0 |
NCT04891757 | Phase I | FHD-286 | FHD-286 in Subjects With Advanced Hematologic Malignancies | Recruiting | USA | 0 |
NCT04898894 | Phase I | Cytarabine + Filgrastim + Fludarabine + Methotrexate + Selinexor + Venetoclax | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04905810 | Phase II | Azacitidine + Decitabine + Venetoclax | Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | Recruiting | USA | 0 |
NCT04912063 | Phase I | Azacitidine + Lemzoparlimab Azacitidine + Lemzoparlimab + Venetoclax | Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitdine With or Without Venetoclax in Participants With Myelodysplastic Syndrome | Terminated | USA | ITA | ISR | ESP | DEU | AUS | 1 |
NCT04913922 | Phase II | Azacitidine + Nivolumab + Relatlimab | Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML (AARON) | Recruiting | DEU | 0 |
NCT04914845 | Phase I | KPT-9274 | KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04915612 | Phase I | CPX-351 + Gemtuzumab ozogamicin | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04926285 | Phase I | Omacetaxine mepesuccinate + Venetoclax | Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT04937166 | Phase I | Azacitidine + DSP107 + Venetoclax | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies | Recruiting | USA | 0 |
NCT04951778 | Phase I | CC-91633 | Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes | Recruiting | USA | GBR | ESP | CAN | AUS | 0 |
NCT04953780 | Phase I | Calaspargase pegol-mknl + Cytarabine + Idarubicin | 2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML | Active, not recruiting | USA | 0 |
NCT04964505 | Phase I | Azacitidine + Uproleselan + Venetoclax | Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04964518 | Phase I | APG-2575 + Azacitidine | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) | Recruiting | USA | AUS | 0 |
NCT04975919 | Phase II | Decitabine and Cedazuridine + Venetoclax | Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT04982354 | Phase Ib/II | Busulfan + CPX-351 + Fludarabine + Melphalan + Midostaurin | Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia | Withdrawn | USA | 0 |
NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 4 |
NCT05010122 | Phase Ib/II | Decitabine and Cedazuridine + Gilteritinib + Venetoclax | ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT05010772 | Phase I | Decitabine and Cedazuridine Decitabine and Cedazuridine + Ivosidenib Decitabine and Cedazuridine + Gilteritinib Decitabine and Cedazuridine + Enasidenib Decitabine and Cedazuridine + Venetoclax | Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission | Recruiting | USA | 0 |
NCT05020665 | Phase III | Anthracycline + Cytarabine Anthracycline + Cytarabine + Entospletinib | A Study to Assess the Efficacy and Safety of Entospletinib in Combination With Intensive Induction and Consolidation Chemotherapy in Adults With Newly Diagnosed Nucleophosmin 1-mutated Acute Myeloid Leukemia | Terminated | USA | POL | ITA | ISR | HUN | FRA | ESP | DEU | CZE | CAN | BRA | 1 |
NCT05024552 | Phase I | CPX-351 + Gilteritinib | Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | Recruiting | USA | 0 |
NCT05024994 | Phase II | E7820 | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers | Active, not recruiting | USA | 0 |
NCT05028751 | Phase Ib/II | Gilteritinib + Lanraplenib | A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) | Terminated | USA | ESP | 0 |
NCT05038644 | Phase I | XmAb18968 | XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia | Active, not recruiting | USA | 0 |
NCT05038800 | Phase I | MK-0482 | A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) (MK-0482-002) | Terminated | USA | ISR | ESP | 0 |
NCT05079230 | Phase III | Azacitidine + Hu5F9-G4 + Venetoclax Azacitidine + Venetoclax | Study Evaluating the Safety and Effectiveness Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia (AML) (ENHANCE-3) | Terminated | USA | POL | NOR | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BEL | AUT | AUS | 3 |
NCT05086315 | Phase Ib/II | SAR443579 | First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | Recruiting | USA | NLD | FRA | AUS | 1 |
NCT05107856 | Phase I | PRT1419 | A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies | Terminated | USA | 0 |
NCT05143996 | Phase I | CLN-049 | CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT05144334 | Phase I | BTX-1188 | A Study of BTX-1188 in Subjects With Advanced Malignancies | Terminated | USA | 0 |
NCT05146739 | Phase I | Cytarabine + Fludarabine + Uproleselan | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane | Active, not recruiting | USA | 0 |
NCT05155709 | Phase Ib/II | Azacitidine + Siremadlin + Venetoclax | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | Completed | USA | TUR | ITA | ISR | HUN | 2 |
NCT05168202 | Phase I | Azacitidine + CC-95251 CC-95251 | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes | Completed | USA | SWE | NOR | ITA | GBR | FRA | ESP | CAN | AUS | 0 |
NCT05168904 | Phase Ib/II | CYC065 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | Suspended | USA | 0 |
NCT05183035 | Phase III | Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin + Venetoclax Azacitidine + Cytarabine + Fludarabine + Gemtuzumab ozogamicin | Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Recruiting | USA | SWE | NZL | NOR | NLD | ITA | ISR | FRA | FIN | ESP | DNK | CZE | CHE | CAN | BEL | AUT | AUS | 1 |
NCT05188170 | Phase I | Niclosamide | Phase 1 Study of Niclosamide in Pediatric Patients With Relapsed and Refractory AML | Recruiting | USA | 0 |
NCT05190471 | Phase I | BP1002 + Decitabine BP1002 | A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | Unknown status | USA | 0 |
NCT05222984 | Phase I | Decitabine + Navitoclax + Venetoclax | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax | Active, not recruiting | USA | 0 |
NCT05263284 | Phase I | 8-Chloroadenosine + Venetoclax | 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia | Suspended | USA | 0 |
NCT05275439 | Phase I | Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Active, not recruiting | USA | GBR | CAN | 0 |
NCT05279859 | Phase Ib/II | ERAS-007 + Gilteritinib | A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies (HERKULES-4) | Withdrawn | USA | 0 |
NCT05287568 | Phase I | Azacitidine + Venetoclax | CC-486 and Venetoclax for Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05292664 | Phase I | Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax | Venetoclax Basket Trial for High Risk Hematologic Malignancies | Recruiting | USA | 0 |
NCT05317403 | Phase I | Azacitidine + Cytarabine + Filgrastim + Fludarabine + Venetoclax + Vorinostat | Venetoclax to Augment Epigenetic Modification and Chemotherapy | Recruiting | USA | 0 |
NCT05326516 | Phase I | Revumenib | A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia | Completed | USA | CAN | 0 |
NCT05330377 | Phase I | Cladribine + Cytarabine + Filgrastim + Gilteritinib + Mitoxantrone | GM-CLAG in Relapsed/Refractory FLT3-mutated AML | Withdrawn | USA | 0 |
NCT05342584 | Phase I | Cytarabine + Daunorubicin + Venetoclax | Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS | Recruiting | USA | 0 |
NCT05360160 | Phase Ib/II | Decitabine and Cedazuridine Revumenib Venetoclax | A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | Recruiting | USA | 0 |
NCT05362773 | Phase I | MGD024 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | Recruiting | USA | 0 |
NCT05377827 | Phase I | WU-CART-007 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | Active, not recruiting | USA | 0 |
NCT05396859 | Phase I | Decitabine and Cedazuridine + Entrectinib | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05400122 | Phase I | Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | Recruiting | USA | 0 |
NCT05401097 | Phase II | Azacitidine + Enasidenib + Venetoclax Azacitidine + Ivosidenib + Venetoclax | IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) | Recruiting | USA | 0 |
NCT05406817 | Phase I | Revumenib | Study of Radiolabeled SNDX-5613 in Adults With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05424380 | Phase I | GSK3745417 | A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS | Terminated | NLD | ITA | ESP | DEU | CAN | 0 |
NCT05428969 | Phase Ib/II | Azacitidine + FP-1305 Azacitidine + FP-1305 + Venetoclax | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) | Recruiting | USA | FIN | 0 |
NCT05431257 | Phase II | Azacitidine + Venetoclax Venetoclax | Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling (LD-VenEx) | Recruiting | DNK | 0 |
NCT05441514 | Phase I | Cobimetinib + Enasidenib | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05447663 | Phase Ib/II | Siremadlin | A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant | Terminated | ITA | ESP | DEU | 0 |
NCT05453903 | Phase I | JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 | A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 0 |
NCT05455294 | Phase I | Decitabine + Navitoclax + Venetoclax | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms | Active, not recruiting | USA | 0 |
NCT05457010 | Phase I | ACLX-002 | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS | Recruiting | USA | 0 |
NCT05470140 | Phase I | WU-NK-101 | A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) | Active, not recruiting | USA | AUS | 0 |
NCT05476770 | Phase I | Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Recruiting | USA | AUS | 0 |
NCT05506332 | Phase I | Mercaptopurine + Venetoclax | Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | BEL | 0 |
NCT05506956 | Phase I | Flotetuzumab | Post-transplant Flotetuzumab for AML | Completed | USA | 0 |
NCT05519527 | Phase I | STI-6129 | A Phase 1, Open-Label, Dose-Escalation Study of Safety And Efficacy of An Anti-CD38 Antibody Drug Conjugate (STI-6129) In Patients With Relapsed Or Refractory T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL) Or Acute Myeloid Leukemia (AML) | Withdrawn | 0 | |
NCT05520567 | Phase Ib/II | Azacitidine + Gilteritinib + Venetoclax | A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05546580 | Phase I | Gilteritinib + ORY-1001 | Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) (FRIDA) | Recruiting | USA | 0 |
NCT05554393 | Phase II | Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax | Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Recruiting | USA | CAN | 1 |
NCT05554406 | Phase II | Cytarabine + Daunorubicin Azacitidine + Venetoclax CPX-351 Cytarabine + Daunorubicin + Venetoclax CPX-351 + Venetoclax | Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Recruiting | USA | 1 |
NCT05558124 | Phase I | CPX-351 + Gemtuzumab ozogamicin | CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | Recruiting | USA | 0 |
NCT05564390 | Phase II | Cytarabine + Venetoclax Cytarabine + Daunorubicin + Venetoclax CPX-351 + Venetoclax Cytarabine + Daunorubicin Cytarabine Azacitidine + Gilteritinib + Venetoclax Azacitidine + Venetoclax CPX-351 | MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Recruiting | USA | CAN | 1 |
NCT05580601 | Phase Ib/II | CIML-NK cells | Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT05583552 | Phase II | Imetelstat | Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress) | Recruiting | FRA | DEU | AUS | 0 |
NCT05597306 | Phase I | IMG-7289 + Venetoclax | Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia (VenBom) | Recruiting | USA | 0 |
NCT05599360 | Phase II | CPX-351 + Gemtuzumab ozogamicin | Vyxeos for Induction of Low- or Intermediate-risk. | Active, not recruiting | ISR | 0 |
NCT05601726 | Phase I | ABD-3001 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients (ODYSSEY) | Recruiting | FRA | 0 |
NCT05627232 | Phase I | CPX-351 + Palbociclib + Tazemetostat | Palbociclib and Tazemetostat in Combination With CPX-351 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05636514 | Phase I | Decitabine and Cedazuridine + Defactinib | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS) | Recruiting | AUS | 0 |
NCT05659732 | Phase I | PEP07 | A Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer | Recruiting | AUS | 1 |
NCT05662904 | Phase I | Gemtuzumab ozogamicin | Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33) | Not yet recruiting | DEU | 0 |
NCT05672147 | Phase I | Anti-CD33 CAR-T cells | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05673057 | Phase Ib/II | MP0533 | Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | NLD | LTU | FRA | CHE | 0 |
NCT05682170 | Phase Ib/II | ZN-c3 + ZN-d5 ZN-c3 | Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | Terminated | USA | 0 |
NCT05697510 | Phase I | Siltuximab | Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM (SILTUXILAM) | Recruiting | FRA | 0 |
NCT05703542 | Phase I | Talabostat mesylate | BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT05712278 | Phase I | SAR445419 Cytarabine + Fludarabine | A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia | Terminated | USA | 0 |
NCT05720988 | Phase I | Tagraxofusp-erzs Azacitidine + Tagraxofusp-erzs | Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia | Withdrawn | USA | 0 |
NCT05732103 | Phase Ib/II | CTX-712 | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Recruiting | USA | 0 |
NCT05735184 | Phase I | Azacitidine + Venetoclax + Ziftomenib Cytarabine + Daunorubicin + Ziftomenib Venetoclax + Ziftomenib | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML | Recruiting | USA | 0 |
NCT05744739 | Phase I | Azacitidine + Tomivosertib + Venetoclax | Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive Chemotherapy | Active, not recruiting | USA | 0 |
NCT05748197 | Phase I | Cyclophosphamide + Fludarabine ADCLEC.syn1 | A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05756322 | Phase Ib/II | LBS-007 | The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | Recruiting | USA | AUS | 1 |
NCT05756777 | Phase I | Gilteritinib + Ivosidenib Enasidenib + Gilteritinib | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT05766514 | Phase II | Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction | Not yet recruiting | USA | 0 |
NCT05775406 | Phase I | KT-253 | Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors | Active, not recruiting | USA | 0 |
NCT05780879 | Phase II | Cytarabine + Filgrastim + Fludarabine + Venetoclax | A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05787496 | Phase I | NC525 | A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms | Active, not recruiting | USA | 0 |
NCT05799079 | Phase II | Decitabine and Cedazuridine + Venetoclax | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant | Recruiting | USA | 0 |
NCT05817058 | Phase I | AFM28 | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | FRA | ESP | DNK | 0 |
NCT05829226 | Phase I | LYT-200 | A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | Recruiting | USA | 0 |
NCT05834244 | Phase I | Azacitidine + Venetoclax | A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | Recruiting | USA | 0 |
NCT05854966 | Phase II | CPI-613 + Metformin | CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Withdrawn | 0 | |
NCT05886049 | Phase I | Cytarabine + Daunorubicin + Revumenib | Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | Recruiting | USA | 0 |
NCT05886491 | Phase Ib/II | Cyclophosphamide + Fludarabine GDX012 | A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05907057 | Phase III | Azacitidine + Ivosidenib | An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | Recruiting | NLD | ITA | FRA | AUT | 0 |
NCT05918692 | Phase I | BMF-500 | A Phase 1, Study of BMF-500 in Adults With Acute Leukemia | Recruiting | USA | 0 |
NCT05933070 | Phase I | INKmune | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL) | Terminated | GRC | GBR | 0 |
NCT05945849 | Phase I | Anti-CD33 CAR-T cells | CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML | Recruiting | USA | 0 |
NCT05949125 | Phase I | Cyclophosphamide + Fludarabine AVC-201 | Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 | Recruiting | NLD | DEU | 0 |
NCT05955261 | Phase II | Azacitidine + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + Venetoclax Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + mitoxantrone hydrochloride + Venetoclax Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Gilteritinib + mitoxantrone hydrochloride + Venetoclax | A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05961839 | Phase I | SGR-2921 | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT05984199 | Phase Ib/II | Anti-CD33 CAR-T cells | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | Recruiting | USA | 0 |
NCT06001788 | Phase I | Gilteritinib + Ziftomenib Cytarabine + Ziftomenib Cytarabine + Filgrastim + Fludarabine + Idarubicin + Ziftomenib | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT06007911 | Phase I | Cladribine + Cytarabine + Navitoclax + Venetoclax Cladribine + Cytarabine + Filgrastim + Mitoxantrone + Navitoclax + Venetoclax | Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Withdrawn | USA | 0 |